Bank of New York Mellon Corp Has $78.35 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Bank of New York Mellon Corp trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 11.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,884,214 shares of the company’s stock after selling 253,068 shares during the quarter. Bank of New York Mellon Corp’s holdings in Moderna were worth $78,346,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Knuff & Co LLC grew its holdings in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares during the period. Stephens Inc. AR grew its holdings in Moderna by 7.9% in the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after purchasing an additional 245 shares during the period. Allworth Financial LP grew its holdings in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. grew its holdings in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares during the period. Finally, Larson Financial Group LLC grew its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on MRNA. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Leerink Partners dropped their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Moderna in a research note on Friday, February 14th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Price Performance

MRNA opened at $30.27 on Tuesday. The firm has a market capitalization of $11.68 billion, a P/E ratio of -3.26 and a beta of 1.59. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The company’s 50-day moving average is $37.12 and its 200 day moving average is $50.28.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.